As CytoDyn (CYDY) Stock Slips below $3, Should You Buy?

Over the course of the past year or so, CytoDyn (OTCMKTS:CYDY) has been in considerable focus among many investors due to its work with leronlimab.

However, due to the events of the past couple of years in relation to leronlimab, experts believe that CytoDyn is a stock that could be traded but may not be particularly suitable for investing. In order to get a better idea about the company, it is important for investors to get a better idea about leronlimab.

It was back in 2019 that the company had publicized the initial approval granted to leronlimab as an effective combination therapy for patients suffering from HIV. However, it has not been smooth sailing for CytoDyn since. In recent times, the company has faced a lot of challenges when it came to presenting the merits of leronlimab to the United States Food and Drug Administration as well. In this situation, it might be a good idea for long-term investors to sit on the sidelines.